EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ocular Safety of Intravitreal Engineered Humanized Anti-VEGF Nanobody and Its Efficacy in the Attenuation of Choroidal Neovascularization and Associated Subretinal Fibrosis

Mir Salar Kazemi, Mozhgan Rezaei Kanavi, Fatemeh Kazemi-Lomedasht iD, Reza Ahangari Cohan, Golnoosh Mahjoobi, Sare Safi, Sadra Ashrafi, Hamid Ahmadieh, Alireza Shoari, Mahdi Behdani

Biomolecules · 25.05.2026 · 16 (6) · 772

DOI: 10.3390/biom16060772 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, online erschienen am 25.05.2026. Verfasst von Mir Salar Kazemi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran 13169-43551, Iran. Hauptthemen laut MEDLINE: Choroidal Neovascularization, Vascular Endothelial Growth Factor A, Single-Domain Antibodies. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pasteur Institute of Iran, Student Research Committee, Pasteur Institute of Iran.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current treatments for choroidal neovascularization (CNV) and its associated subretinal fibrosis (SRF), major causes of vision loss, are limited by the need for frequent intravitreal injections and the emergence of drug resistance. This study evaluated the safety and efficacy of the intravitreal administration of engineered humanized anti-vascular endothelial growth factor Nanobodies, including a wild-type Nanobody (WHNb) and two mutated variants (MHNb136 and MHNb256), in a rat model of laser-induced CNV and associated SRF. Safety was assessed through in vivo electrophysiological and histopathological analyses following intravitreal injection of Nanobodies at doses of 12.5, 25, 50, and 100 µg. Efficacy was evaluated in rat models of laser-induced CNV and SRF using double immunohistochemistry for isolectin B4 and anti-collagen type I on sclerochoroidal flat mounts. Mean CNV and SRF areas in Nanobody-treated groups were compared with those in bevacizumab-treated and sham control groups. None of the Nanobodies showed retinal toxicity in safety assessments. Compared with bevacizumab, MHNb136 and MHNb256 reduced the CNV area by 1.72-fold and 1.8-fold, respectively (both p < 0.0001), whereas WHNb showed an effect nearly identical to that of bevacizumab. In addition, 12.5 µg MHNb136 and 100 µg MHNb256 reduced the SRF area by 1.3-fold (p = 0.047) and 1.6-fold (p = 0.0007), respectively, relative to bevacizumab. For CNV reduction, 12.5 µg MHNb136 was comparable to 25 µg MHNb256; both outperformed bevacizumab. For SRF reduction, 12.5 µg MHNb136 was more effective than bevacizumab and comparable to 100 µg MHNb256. These findings suggest that 12.5 µg MHNb136 may represent a cost-effective bioengineered Nanobody candidate for future clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Choroidal NeovascularizationVascular Endothelial Growth Factor ASingle-Domain AntibodiesAnimalsFibrosisRatsIntravitreal InjectionsHumansMaleBevacizumabRetinaDisease Models, AnimalAngiogenesis InhibitorsRats, Sprague-Dawley

Stichwörter der Autor:innen

angiogenesischoroidal neovascularizationinflammationintravitreal injectionnanobodysubretinal fibrosis

Substanzen

Vascular Endothelial Growth Factor ASingle-Domain AntibodiesBevacizumabAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran 13169-43551, Iran.
  • Student Research Committee, Pasteur Institute of Iran, Tehran 13169-43551, Iran.
  • Ocular Tissue Engineering Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran 16666-73111, Iran.
  • Nanobiotechnology Department, New Technologies Research Group, Pasteur Institute of Iran, Tehran 13169-43551, Iran.
  • Ophthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran 16666-73111, Iran.
  • Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran 16666-73111, Iran.

ORCID-Profile: Fatemeh Kazemi-Lomedasht

Förderung

  • Pasteur Institute of Iran
  • Student Research Committee, Pasteur Institute of Iran

Zitieren

APA

Kazemi, M. S., Rezaei Kanavi, M., Kazemi-Lomedasht, F., Ahangari Cohan, R., Mahjoobi, G., Safi, S., Ashrafi, S., Ahmadieh, H., Shoari, A., & Behdani, M. (2026). Ocular Safety of Intravitreal Engineered Humanized Anti-VEGF Nanobody and Its Efficacy in the Attenuation of Choroidal Neovascularization and Associated Subretinal Fibrosis. Biomolecules, 16(6), 772. https://doi.org/10.3390/biom16060772

Vancouver

Kazemi MS, Rezaei Kanavi M, Kazemi-Lomedasht F, Ahangari Cohan R, Mahjoobi G, Safi S, et al. Ocular Safety of Intravitreal Engineered Humanized Anti-VEGF Nanobody and Its Efficacy in the Attenuation of Choroidal Neovascularization and Associated Subretinal Fibrosis. Biomolecules. 2026;16(6):772. doi:10.3390/biom16060772

BibTeX
@article{Kazemi2026,
  author = {Kazemi, Mir Salar and Rezaei Kanavi, Mozhgan and Kazemi-Lomedasht, Fatemeh and Ahangari Cohan, Reza and Mahjoobi, Golnoosh and Safi, Sare and Ashrafi, Sadra and Ahmadieh, Hamid and Shoari, Alireza and Behdani, Mahdi},
  title = {Ocular Safety of Intravitreal Engineered Humanized Anti-VEGF Nanobody and Its Efficacy in the Attenuation of Choroidal Neovascularization and Associated Subretinal Fibrosis},
  journal = {Biomolecules},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {772},
  doi = {10.3390/biom16060772}
}
Kostenlos starten →